Indoco Remedies Limited, a leading Indian pharmaceutical company, announced today that its Active Pharmaceutical Ingredients (API) manufacturing facility at Patalganga, Navi Mumbai, has successfully passed the United States Food and Drug Administration (USFDA) inspection. Impressively, the inspection concluded with zero Form 483 observations, underscoring the company’s unwavering commitment to quality, regulatory compliance, and operational excellence.
The successful inspection highlights Indoco Remedies’ strong focus on maintaining world-class quality standards in its manufacturing processes. Aditi Panandikar, Managing Director of Indoco Remedies Limited, stated, “This successful USFDA inspection is a testament to the strong quality culture and compliance in every process and every product. We remain committed to strengthening our systems to deliver safe and efficacious medicines across the globe.”
With this milestone, Indoco Remedies reinforces its position as a trusted supplier of high-quality APIs and formulations to global markets, ensuring that patients worldwide have access to safe and effective medicines.
